Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

Cross-sectional Biomarker Study for Vascular Calcification in Hemodialysis Patients

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Inclusion Criteria:

• Stable hemodialysis > 3 months duration

Exclusion Criteria:

• Pregnancy
• Acute infections or antibiotic treatment (within 4 weeks)